Revolution Medicines (42Z) Stock Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

42Z Analyst Ratings

Strong Buy

20 Buy

1 Hold

0 Sell

Based on 21 analysts giving stock ratings to

Revolution

Medicines

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

42Z Stock 12 Month Forecast

Average Price Target

€165.12

▲(25.57% Upside)

Based on 21 Wall Street analysts offering 12 month price targets for Revolution Medicines in the last 3 months. The average price target is €165.12 with a high forecast of €229.84 and a low forecast of €122.35. The average price target represents a 25.57% change from the last price of €131.50.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"€30","80":"€80","130":"€130","180":"€180","230":"€230"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":229.83684141999998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€229.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":165.12422504299997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€165.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":122.3466076,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€122.35</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,80,130,180,230],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,164.25,169.2951416476923,174.3402832953846,179.3854249430769,184.43056659076922,189.47570823846152,194.52084988615383,199.56599153384616,204.61113318153843,209.65627482923077,214.70141647692304,219.74655812461538,224.79169977230768,{"y":229.83684141999998,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,164.25,164.31724808023077,164.38449616046154,164.4517442406923,164.51899232092308,164.58624040115384,164.6534884813846,164.72073656161535,164.78798464184612,164.8552327220769,164.92248080230766,164.98972888253843,165.0569769627692,{"y":165.12422504299997,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,164.25,161.02666212307693,157.80332424615384,154.57998636923077,151.3566484923077,148.13331061538463,144.90997273846153,141.68663486153847,138.4632969846154,135.2399591076923,132.01662123076923,128.79328335384616,125.56994547692307,{"y":122.3466076,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.8,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.6,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 77,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":164.25,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€229.84

Average Price Target€165.12

Lowest Price Target€122.35

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

07/02/26

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD) and Johnson & Johnson (NYSE: JNJ)

Charles Zhu

LifeSci Capital

€161.67→€229.84

Buy

74.78%

Upside

Assigned

07/02/26

Revolution Medicines: Strong Zoldonrasib Data in G12D Pancreatic Cancer Support Buy Rating and Unchanged $263 Price Target

Gregory Renza

Truist Financial

€156.43→€183.52

Buy

39.56%

Upside

Reiterated

06/30/26

Revolution Medicines price target raised to $210 from $179 at TruistRevolution Medicines price target raised to $210 from $179 at Truist

Ami Fadia

Needham

€159.92→€205.37

Buy

56.17%

Upside

Assigned

06/29/26

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Vertex Pharmaceuticals (NASDAQ: VRTX) and Monopar Therapeutics Inc (NASDAQ: MNPR)

Laura Prendergast

Stifel Nicolaus

€187.89

Buy

42.88%

Upside

Reiterated

06/29/26

Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Apogee Therapeutics (APGE)

Leonid Timashev

RBC Capital

€159.05

Buy

20.95%

Upside

Reiterated

06/26/26

Analysts' Top Healthcare Picks: Johnson & Johnson (JNJ), Legend Biotech (LEGN)

Michael Schmidt

Guggenheim

€179.15

Buy

36.24%

Upside

Reiterated

06/25/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Brian Cheng

J.P. Morgan

€152.93→€174.78

Buy

32.91%

Upside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Tyra Bioscience (NASDAQ: TYRA) and Revolution Medicines (NASDAQ: RVMD)

Alec Stranahan

Bank of America Securities

€161.67→€185.27

Buy

40.89%

Upside

Reiterated

06/25/26

Bank of America Securities Sticks to Its Buy Rating for Revolution Medicines (RVMD)

Michael Yee

UBS

€152.93

Buy

16.30%

Upside

Reiterated

06/08/26

Revolution Medicines: RAS Combination Data and Phase III Plans Reinforce Pipeline Upside; Buy Rating and $175 Price Target Reiterated

Robert Burns

H.C. Wainwright

€147.69→€170.41

Buy

29.59%

Upside

Reiterated

06/02/26

Revolution Medicines price target raised to $195 from $169 at H.C. WainwrightRevolution Medicines price target raised to $195 from $169 at H.C. Wainwright

Eva Fortea Verdejo

Wells Fargo

€174.78→€145.94

Buy

10.98%

Upside

Assigned

06/01/26

Wells Fargo Sticks to Its Buy Rating for Revolution Medicines (RVMD)

Jay Olson

Oppenheimer

€144.19→€170.41

Buy

29.59%

Upside

Assigned

06/01/26

Oppenheimer Remains a Buy on Revolution Medicines (RVMD)

Robert Driscoll

Wedbush

€144.19

Buy

9.65%

Upside

Reiterated

06/01/26

Wedbush Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

Kelsey Goodwin

Piper Sandler

€104.87→€150.31

Buy

14.31%

Upside

Reiterated

05/07/26

Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), BioCryst (BCRX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

07/02/26

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD) and Johnson & Johnson (NYSE: JNJ)

Charles Zhu

LifeSci Capital

€161.67→€229.84

Buy

74.78%

Upside

Assigned

07/02/26

Revolution Medicines: Strong Zoldonrasib Data in G12D Pancreatic Cancer Support Buy Rating and Unchanged $263 Price Target

Gregory Renza

Truist Financial

€156.43→€183.52

Buy

39.56%

Upside

Reiterated

06/30/26

Revolution Medicines price target raised to $210 from $179 at TruistRevolution Medicines price target raised to $210 from $179 at Truist

Ami Fadia

Needham

€159.92→€205.37

Buy

56.17%

Upside

Assigned

06/29/26

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD), Vertex Pharmaceuticals (NASDAQ: VRTX) and Monopar Therapeutics Inc (NASDAQ: MNPR)

Laura Prendergast

Stifel Nicolaus

€187.89

Buy

42.88%

Upside

Reiterated

06/29/26

Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Apogee Therapeutics (APGE)

Leonid Timashev

RBC Capital

€159.05

Buy

20.95%

Upside

Reiterated

06/26/26

Analysts' Top Healthcare Picks: Johnson & Johnson (JNJ), Legend Biotech (LEGN)

Michael Schmidt

Guggenheim

€179.15

Buy

36.24%

Upside

Reiterated

06/25/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Brian Cheng

J.P. Morgan

€152.93→€174.78

Buy

32.91%

Upside

Reiterated

06/25/26

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (NASDAQ: PVLA), Tyra Bioscience (NASDAQ: TYRA) and Revolution Medicines (NASDAQ: RVMD)

Alec Stranahan

Bank of America Securities

€161.67→€185.27

Buy

40.89%

Upside

Reiterated

06/25/26

Bank of America Securities Sticks to Its Buy Rating for Revolution Medicines (RVMD)

Michael Yee

UBS

€152.93

Buy

16.30%

Upside

Reiterated

06/08/26

Revolution Medicines: RAS Combination Data and Phase III Plans Reinforce Pipeline Upside; Buy Rating and $175 Price Target Reiterated

Robert Burns

H.C. Wainwright

€147.69→€170.41

Buy

29.59%

Upside

Reiterated

06/02/26

Revolution Medicines price target raised to $195 from $169 at H.C. WainwrightRevolution Medicines price target raised to $195 from $169 at H.C. Wainwright

Eva Fortea Verdejo

Wells Fargo

€174.78→€145.94

Buy

10.98%

Upside

Assigned

06/01/26

Wells Fargo Sticks to Its Buy Rating for Revolution Medicines (RVMD)

Jay Olson

Oppenheimer

€144.19→€170.41

Buy

29.59%

Upside

Assigned

06/01/26

Oppenheimer Remains a Buy on Revolution Medicines (RVMD)

Robert Driscoll

Wedbush

€144.19

Buy

9.65%

Upside

Reiterated

06/01/26

Wedbush Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

Kelsey Goodwin

Piper Sandler

€104.87→€150.31

Buy

14.31%

Upside

Reiterated

05/07/26

Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), BioCryst (BCRX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

TRAXFirst Tracks Biotherapeutics Inc

EVMNEvommune, Inc.

MPLTMapLight Therapeutics, Inc.

MAZEMaze Therapeutics, Inc.

AAPGAscentage Pharma Group International Unsponsored ADR

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Revolution Medicines

3 Months

Joseph CatanzaroMizuho Securities

Success Rate

10/12 ratings generated profit

Average Return

+27.87%

Copying Joseph Catanzaro's trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +27.87% per trade.

1 Year

Michael SchmidtGuggenheim

Success Rate

16/16 ratings generated profit

Average Return

+106.90%

Copying Michael Schmidt's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +106.90% per trade.

2 Years

Peter LawsonBarclays

Success Rate

13/13 ratings generated profit

Average Return

+334.40%

Copying Peter Lawson's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +334.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

42Z Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 42Z has received 45 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. 42Z average Analyst price target in the past 3 months is 165.12.

Each month's total comprises the sum of three months' worth of ratings.

42Z Financial Forecast

42Z Earnings Forecast

Next quarter’s earnings estimate for 42Z is -€1.71 with a range of -€1.91 to -€0.74. The previous quarter’s EPS was -€2.00. 42Z beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 42Z has Performed in-line its overall industry.

42Z Sales Forecast

Next quarter’s sales forecast for 42Z is €15.78M with a range of €0.00 to €218.48M. The previous quarter’s sales results were €0.00. 42Z beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 42Z has Performed in-line its overall industry.

42Z Stock Forecast FAQ

What is DE:42Z’s average 12-month price target, according to analysts?

Based on analyst ratings, Revolution Medicines, Inc.’s 12-month average price target is 165.12.

What is DE:42Z’s upside potential, based on the analysts’ average price target?

Revolution Medicines, Inc. has 25.57% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Revolution Medicines, Inc. a Buy, Sell or Hold?

Revolution Medicines, Inc. has a consensus rating of Strong Buy, which is based on 20 buy ratings, 1 hold ratings and 0 sell ratings.

What is Revolution Medicines, Inc.’s share price target?

The average share price target for Revolution Medicines, Inc. is 165.12. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €229.84 ,and the lowest forecast is €122.35. The average share price target represents 25.57% Increase from the current price of €131.5.

What do analysts say about Revolution Medicines, Inc.?

Revolution Medicines, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.

How can I buy shares of Revolution Medicines, Inc.?

To buy shares of DE:42Z, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Revolution Medicines (42Z) Stock Forecast & Price Target

42Z Analyst Ratings

42Z Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Revolution Medicines

42Z Analyst Recommendation Trends

42Z Financial Forecast

42Z Earnings Forecast

42Z Sales Forecast

42Z Stock Forecast FAQ

Detailed List of Analyst Forecasts